ADMA stock icon

ADMA Biologics

21.78 USD
-0.70
3.11%
At close Nov 12, 4:00 PM EST
After hours
22.19
+0.41
1.88%
1 day
-3.11%
5 days
10.73%
1 month
33.05%
3 months
32.40%
6 months
147.78%
Year to date
378.68%
1 year
482.35%
5 years
419.81%
10 years
77.80%
 

About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Employees: 624

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2,302% more call options, than puts

Call options by funds: $12.7M | Put options by funds: $527K

176% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 21

73% more capital invested

Capital invested by funds: $1.2B [Q1] → $2.07B (+$872M) [Q2]

17% more funds holding

Funds holding: 213 [Q1] → 250 (+37) [Q2]

6% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 83

0.17% more ownership

Funds ownership: 79.77% [Q1] → 79.94% (+0.17%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
17%
downside
Avg. target
$22
2%
upside
High target
$26
19%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
49% 1-year accuracy
155 / 314 met price target
19%upside
$26
Buy
Maintained
8 Nov 2024
Raymond James
Elliot Wilbur
100% 1-year accuracy
4 / 4 met price target
15%upside
$25
Strong Buy
Maintained
8 Nov 2024
HC Wainwright & Co.
Raghuram Selvaraju
49% 1-year accuracy
155 / 314 met price target
17%downside
$18
Buy
Reiterated
14 Oct 2024
Cantor Fitzgerald
Kristen Kluska
57% 1-year accuracy
60 / 105 met price target
8%downside
$20
Overweight
Reiterated
20 Sept 2024

Financial journalist opinion

Based on 113 articles about ADMA published over the past 30 days

Charts implemented using Lightweight Charts™